RESEARCH ARTICLE

CURRENT CONCEPTS AND TECHNIQUES IN ENHANCEMENT OF FRACTURE HEALING IN CANINES: A REVIEW.

Sandeep Saharan¹ and Ribu Varghese Mathew².

1. Assistant Professor, Department of Veterinary Clinical Complex, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar.
2. M.V.Sc Scholar, Department of Veterinary Surgery and Radiology, College of Veterinary Sciences, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar.

Abstract

Traditionally used metallic implants for fracture stabilisation even though have potential capability for fracture healing have been associated with significant disadvantages like patient incompliance and implant loosening leading to mal union, non-union and dis-union. Veterinary orthopaedics during the last decade has visualised a significant development with respect to use of biomaterials particularly in the field of fracture treatment and stabilisation. A large variety of biomaterials are available in the form of bone grafts and bone substitutes for commercial use to treat significant bone defects due to trauma and to enhance the rate of fracture healing. The present article aims to give an insight into the various bone grafts and bone substitutes available, their potential uses, applications, advantages and limitations in veterinary field.

Introduction:

Fractures are defined as the break in the continuity of the bone and is characterised by pain, immobility and loss of function. Fractures in animals invariably causes pain and suffering to them apart from loss of function of the affected limb (Vardhan et al., 2017). Various internal and external skeletal fixation devices have been used in veterinary practice for stabilisation of fracture with variable results. Thus enhancement of fracture healing and achieving complete fracture union as fast and early as possible has become the goal of modern veterinary orthopaedics. The main goal of fracture treatment is to achieve the normal anatomic alignment of the bones and to maintain the bone segments in apposition until complete healing occurs. Open reduction remains the standard technique of fracture treatment in veterinary practice. Traditionally many bioinert metallic implants in the form of intramedullary pins and nails, plates and screws and external skeletal fixators have been used. But these have been associated with delayed union, mal union and non-union mainly due to excessive movement of the patient and resultant implant loosening. Modern methods of fracture treatment involves the use of natural, semi-synthetic or synthetic bone grafts or bone substitutes to fill the gap between the defect and to hold the implant against the bone thereby enhancing bone healing, hastening the fracture union and avoiding complications like implant loosening, migration, non-union, mal-union and delayed union. Many such bone filling agents are available for use by practicing veterinarian that enhances the fracture healing and holds the implant against the bone thereby keeping the fracture segments stable which helps in enhanced osteogenesis.
Current Concepts in Enhancement of Fracture Healing

Bone regeneration is comprised of a well-orchestrated series of biological events of bone induction and conduction, involving a number of cell types and intracellular and extracellular molecular signalling pathways with a definable temporal and spatial sequence in an effort to optimise skeletal repair and restore skeletal function (Cho et al., 2002). Repair of fracture involves a sequence of dynamic events which ultimately restores the integrity of bone and its biomechanical properties (Einhorn, 1998). Bone repair requires four critical elements: osteogenic cells, osteoinductive signals provided by growth factors, an osteoconductive matrix, adequate blood and nutrient supply (Vardhan et al., 2017). All these required elements are provided by biomaterials. Biomaterials are biocompatible materials used inside the body to treat or augment disease conditions. In veterinary practice, biomaterials are used mainly to treat bone fractures. Such biomaterials are capable of providing an environment that simulates the natural conditions of the body. In addition it also provides key components in bone fracture repair. Traditionally the biomaterials used for fracture treatment include bioinert intramedullary pins, screws and plates made of stainless steel and titanium. But these have been associated with mal union, non-union and delayed union mainly because of the considerable degree of movement between the fracture segments. Modern fracture fixation system involves the use of natural, semi-synthetic and synthetic bone grafts and bone substitutes that gets degraded over a period of time and enhances bone healing and promotes clinical union with lesser complications by stabilising the fracture segments in apposition. The ideal material used for fracture fixation must be biocompatible, resorbable and porous to facilitate rapid vascularization and progressive replacement by newly formed bone tissue (Hannouche et al., 2001).

Fracture healing can be enhanced by the use of various growth factors, bone grafts and bone substitutes. The most commonly used materials to promote bone healing are bone grafts (autografts and allografts), bioceramics (Hydroxyapatite, Tricalcium phosphate, Dicalcium phosphate, Calcium sulphate, Bioactive glass), biopolymers (Polylactic acid, Polyglycolic acid, PMMA) and metals (Stainless steel, titanium and its alloys) (Vardhan et al., 2017). Use of bone grafts and bone substitutes like bioceramics and biopolymers either alone or in combination with traditionally used fixation implants to enhance fracture healing have been the latest development in the field of veterinary orthopaedics. These biomaterial scaffolds serve primarily as osteoinductive moieties on which newly formed bone deposits through creeping substitution from adjacent living bone (Groeneveld et al., 1999). They provide structural support to fractures and should be able to withstand certain levels of loading (Huang et al., 2012).

Growth Factors

Growth factors play a vital role in healing of any damaged tissue whether it’s soft tissue or bone. Bone releases several growth factors at the site of the fracture including bone morphogenic proteins (BMP), TGF-beta, PDGF, IGF-I, IGF-II and basic and acidic Fibroblast Growth Factor (FGF). Bone Morphogenic Proteins are the only factor known to induce bone formation heterotopically by inducing undifferentiated mesenchymal cells to differentiate into osteoblasts (Hannouche et al., 2001). The release of fibroblast growth factor play an important role in the initial phase of healing process, since they have shown angiogenic properties and mitogenic activity on the osteoblast lineage (Bostrom et al., 1999). Bone marrow is a rich source of all these growth factors and hence use of bone marrow at the fracture site can enhance fracture healing by the release of these growth factors.

Bone Morphogenic Proteins are soluble, bioactive signalling proteins that include many factors implicated in osteoinduction (Huang et al., 2012). BMPs are the only factors known to induce bone formation heterotopically by inducing undifferentiated mesenchymal cells to differentiate into osteoblasts (Hannouche et al., 2001). They induce the mitogenesis of mesenchymal stem cells and other osteoprogenitor and their differentiation towards osteoblasts (Dimitriou et al., 2011). These BMPs have been used in variety of clinical conditions including non-union, open fractures, joint fusions, aseptic bone necrosis and critical bone defects (Giannoudis and Einhorn, 2009).

Bone Grafts and Bone Substitutes

Present medical and veterinary surgical practice involves the use of bone grafts and bone substitutes to replace or regenerate the bone defects. The principle of bone tissue engineering is based on using natural or synthetic scaffolds that are biocompatible and similar to the bone matrix (Salamasi et al., 2016). The graft materials required to fill the fracture gap should promote healing by osteoinduction, osteogenesis and osteoconduction and minimize complications like non-unions or delayed unions (Bishnoi, 2013). Bone grafting is a commonly performed surgical procedure to augment bone regeneration in a variety of orthopaedic and maxillofacial procedures with autologous bone being considered as the gold standard bone grafting material as it combines all properties required in a bone graft material like osteoinduction (BMPs and other growth factors), osteogenesis (osteoprogenitor cells) and
osteocconduct (scaffold) (Bauer and Muschler, 2000). Significant bone defects or post traumatic complications such as delayed union, non-union or mal union may require bone grafting in order to fill the defect.

**Bone grafts**

Cellular events in fracture repair are controlled to a large part by growth factors and low molecular weight glycoproteins which induce migration, proliferation and differentiation of an appropriate subset of cells in the site of fracture (Hannouche et al., 2001). These elements involved in fracture healing are naturally present in bone grafts and hence can be implanted at the site of fracture to enhance bone healing. Bone grafts functions as a source for osteogenesis, osteoinduction and even mechanical support (Basset, 1972). Natural bone grafts include autogenous bone grafts, allogenic bone grafts and bone marrow.

**Autogenous Bone Grafts**

Autogenous bone grafts are considered as the gold standard for bone replacement mainly because they offer minimum immunologic reaction, complete histocompatibility and provide best osteoconductive, osteogenic and osteoinductive properties (Samartzis et al., 2005). Autogenous bone grafts are of two types: Autogenous Cancellous bone grafts and Autogenous Cortical Bone Grafts. Autogenous cancellous bone is the most commonly used bone graft which is readily available and easily harvestable but it lacks mechanical strength (Beaumont, 1970). Autogenous cancellous bone grafts has been considered more osteogenic as compared to cortical grafts because of the presence of spaces within their structure that allows diffusion of nutrients and limited revascularisation by microanastomosis of its circulating vessels (Khan et al., 2005). Autogenous cancellous grafts mainly acts mainly as an osteoconductive substrate which efficiently supports the ingrowth of new blood vessels and infiltration of new osteoblasts and osteoblasts precursors (Marx and Wong, 1987). Autogenous cancellous bone grafting is indicated when early production of bone and rapid healing is desired (Vaccaro, 2002). A variety of sites can be used for bone graft harvesting with the anterior and posterior iliac crests of pelvis being the most common donor sites (Dimitriou et al., 2011). Intramedullary canal of long bone has been used as an alternative harvesting site providing a large volume of autologous bone graft (Giannoudis et al., 2009). Johnson (1986) and Penwick et al (1991) stated that fresh autogenous cancellous grafts is more osteogenic than other bone grafts and the most common harvest sites in dogs and cats are the proximal humerus and proximal tibia (Bishnoi, 2013). These offer structural support to implanted devices and ultimately become mechanically efficient structures as they are incorporated into surrounding bone through creeping substitution (Greenwald et al., 2001). Autologous bone grafts even though considered as gold standard graft material are associated with a number of disadvantages like donor site morbidity, pain, haematoma or infection (Damien and Passons, 1991; Meister et al., 1990). Harvesting requires an additional surgical procedure with well documented complications and discomfort for the patient and has additional disadvantage of quantity restriction and substantial costs (Younger and Chapman, 1989). But autologous bone is biocompatible and non-immunogenic, reducing the immunoreactivity and transmission of infections (Dimitriou et al., 2011).

**Allogenic Bone Grafts**

Allogenic bone grafts are obtained from cadavers and such grafts has both osteoinductive and osteoconductive properties but lack osteogenic properties because of absence of viable cells (Habibovic and de Groot, 2007). Allogenic bone grafts are available as Demineralized Bone Matrix (DBM), morselized and cancellous chips, corticocancellous and cortical grafts and osteochondral and whole bone segments (Dimitriou et al., 2011). The advantages of allogenic bone grafts is their easy availability, can be obtained as per required size and shape, avoids the use of host structures thereby reducing morbidity and has reduced chances of immunoreactivity. But such grafts are associated with increased risk of disease transmission. Harvesting and storage of such grafts provides additional problems in the practical use of these grafts.

The use of grafts either autogenous or allogenic bone graft alone do not ensure optimum healing. A number of other factors also tends to play a role in healing process with the use of grafts. Time interval between procurement and transplantation of graft is an important factor (Bohatyrewicz et al., 2006). It is said that an autogenous bone graft retains its viability for upto 2 hours when kept in normal saline (Laursen et al., 2003). In addition an accurate contact must be ensured between the graft and the graft bed for optimum healing. Vascular supply, lack of infections and surrounding microenvironment also influences fracture healing.

**Bone Marrow**

Bone marrow has been used to stimulate bone formation in skeletal defects and non-union through cytokines and growth factors secreted by the transplanted cells (Connolly, 1995). Lindholm et al. (1982) stated that bone marrow
contains osteoprogenitor stem cells that are able to form bone when combined with various elements of an osseous matrix. Bone marrow is a rich source of growth factors and other osteogenic cells. The delivery of bone marrow aspirates from the recommended sites to the fracture region can enhance fracture healing to a significant extent since these bone marrow aspirates are rich in bone morphogenic proteins and other growth factors.

**Bone Substitutes**

Bone graft substitutes are an alternative to autogenous or allogenic bone grafts. They consist of scaffolds made of synthetic or natural biomaterials that promote the migration, proliferation and differentiation of bone cells for regeneration (Dimitriou et al., 2011). The concerns over the use and availability of autogenous or allogenic bone graft materials have prompted studies aimed at developing suitable synthetic bone substitutes (Pilliar et al., 2001). An ideal bone graft substitute material must be osteoconductive in order to allow as rapid as possible integration with the host bone, biodegradable at a perfect rate in order to eventually be replaced by newly formed natural bone and strong enough to fulfill required load bearing functions at least during the early post implantation period (Pilliar et al., 2001). Bone substitutes should be highly efficient in terms of bone ingrowth to allow a faster regeneration and a better functional recovery (Mastrogiacomo et al., 2006). The bone graft substitutes include naturally occurring materials like bovine collagen mineral composites, Hydroxyapatite and Synthetic materials like calcium sulphate, calcium phosphate and bioactive glass. The efficacy of these materials in the fracture healing depends on stability of fracture fixation (Bishnoi, 2013). Among the bone substitutes, bioceramics (Calcium phosphates and Hydroxyapatite) are very promising candidate in bone substitutes because of their bone like chemical composition and mechanical properties (Mastrogiacomo, 2006). The advantages of bone graft substitutes are their availability in large quantities, shape and size but such materials lack osteogenic and osteoinductive potential and hence an osteogenic or osteoinductive material should be added to make a composite graft to promote osteogenic potentials (Zamprogno, 2004).

**Natural Bone Graft Substitutes**

**Collagen**

The main component of the bone are collagen and hydroxyapatite matrix which is osteoconductive in behaviour. Collagen acts as a matrix over which the bone cells gets attached and stimulate bone formation. Collagen can be used alone or in combination with other bone graft substitutes to promote bone healing. In many research purposes, collagen in combination with hydroxyapatite have been used as bone substitutes and reliable results have been obtained.

**Lignin**

Lignin is a complex natural polymer that is biocompatible and has great potential in association with hydroxyapatite as a biomaterial for bone repair (Martinez et al., 2009). Lignin is also known to have antimicrobial and antioxidant properties and hence can be used even in infected and contaminated sites also. Addition of lignin with other bone cements is known to increase the strength 4-6 times and toughness by an order of magnitude (Sun et al., 2007). Composites can also be made flexible with addition of chitosan in higher contents (Chow, 2009) and this is advantageous in grafting at irregular and non-uniform sites.

**Chitosan**

Chitosan, a natural product derived from the polysaccharide chitin, an abundantly available natural biopolymer found in the exoskeleton of crustaceans like shrimps, crabs, lobster and other shell fish would be an effective material to repair bone defects due to its biocompatibility (Mukherjee et al., 2003). Chitosan is a naturally occurring polymer based composite biomaterial that have attracted considerable attention for bone tissue engineering purposes owing to their pore forming ability, binding capacity with anionic molecules, antibacterial activity and biodegradation (Venkatesan and Kim, 2014). The main disadvantage associated with use of chitosan is that these materials require close proximity with the host bone to achieve optimum healing by osteoconduction. The composite of chitosan and hydroxyapatite has shown good biocompatibility and osteoconduction in reconstruction of bone defects (Yuan et al., 2008). Chitosan fibers which has excellent properties such as biocompatibility, biodegradability and non-toxicity can significantly improve the mechanical properties of calcium phosphate cement (Huang et al., 2012).

**Synthetic Bone Graft Substitutes**

The advent of synthetic materials for bone fixation is of paramount importance in orthopaedic surgery (Bostman, 1991). Many synthetic materials as bone substitutes are easily available including metals, polymers, ceramics and
glasses (Mastrogiacomo et al., 2006). The first study concerning biodegradable materials used for implantation was presented in 1966 by Kukri et al who studied the biocompatibility of poly-L-lactic acid (PLLA) in animals (Kontakis et al., 2007). The most bioactive materials include calcium phosphate ceramics and silicon based bioglasses characterised by the formation of a very tight chemical bond with the bone (Popkov et al., 2016).

**Hydroxyapatite**

Hydroxyapatite is a biocompatible ceramic produced through a high temperature reaction and is highly crystalline form of calcium phosphate (Nandi et al., 2010). Hydroxyapatite was first introduced because of its similarity with mineral phase of the bone (Hannouche et al., 2001). The most unique property of this material is chemical similarity with the mineralized phase of bone. This similarity accounts for their osteoconductive potential and excellent biocompatibility (Ghosh et al., 2008). Hydroxyapatite has been established to be an excellent carrier of osteoinductive growth factor and osteogenic cell populations which greatly add to their utility as bioactive delivery vehicles in the fracture (Noshi et al., 2000). Porosity of hydroxyapatitic material also tends to influence the healing properties. Microporosity allows body fluid circulation whereas macroporosity provides scaffold for bone cell colonization (Daculsi, 1988). Synthetic hydroxyapatite has been long known as one of the best coating materials for metallic implant due to its biocompatible, osteoconductive and osteoinductive properties (Fidancevska et al., 2007).

**Calcium Sulphate and Calcium Phosphate Bioceramics**

Calcium sulphate and calcium phosphate bioceramics are considered as promising synthetic bone graft substitutes particularly because of their comparable chemical and mechanical properties to that of natural bone. These materials mimic the mineral phase of the bone and are resorbed at a rate similar to the rate of new bone formation. Hence these are able to provide some structural support and prevent ingrowth of fibrous tissue while facilitating creeping substitution by host bone (Bishnoi, 2013). Bioceramics have excellent bone-bonding capacities but they are brittle and have poor resistance to compressive stress (Hannouche et al., 2001). Bioceramics have been proven efficient as bone substitutes as these are available in large amounts, are biocompatible, bioactive and osteoconductive (Nicalazo et al., 2003).

Calcium phosphates are osteoconductive and undergo gradual remodelling over time in a pattern similar to that of normal bone (Refai et al., 2004). Within few minutes after injection, calcium phosphate cement hardens due to crystallization. As the injected calcium phosphate interdigitates with the adjacent bone, a structure is formed that is more stable than either cancellous bone grafts or the pellets or blocks of hydroxyapatite, calcium phosphate, calcium sulphate often used to fill spaces (Larsson and Hannink, 2011). Fully cured calcium phosphate has a compressive strength between that of cancellous bone and cortical bone but tensile and shear strength are much lower than cancellous bone. Osteoclastic resorption of the cement, vascular penetration and bone formation occurs in a pattern that suggests remodelling similar to that of normal bone (Larsson, 2006). A proposed mechanism suggests that osteoinductive biomolecules such as bone morphogenetic protein 2 (BMP-2) are adsorbed onto the surface of calcium phosphate bioceramics after their implantation and these adsorbed osteoinductive biomolecules then initiate bone formation which appears as osteoinduction (Cheng et al., 2007). Calcium phosphates are available in two forms: Tricalcium phosphate and Dicalcium phosphate. The rate of resorption of calcium phosphate ceramics vary inversely with the calcium: phosphate ratio and also depends on the density, the size and the porosity. Tricalcium phosphate with a ratio of 1.5 is highly resorbable compared with hydroxyapatite having ratio of 1.67. Porous calcium phosphate implants prepared by sintering at lower temperature showed a higher osteoinductivity than those sintered at higher temperature (Ouayoun et al., 1992). Sintering at lower temperature produced higher specific surface area that allowed adsorption of more bone morphogenetic proteins (Cheng et al., 2010).

Calcium sulphate is one of the first biomaterials used in bone reconstruction in medicine for over 100 years as a resorbable biomaterial for bone grafting (Szponder et al., 2013). Calcium sulphate bioceramics immediately starts to degrade after implantation in a bone defect by passive dissolution caused by an ion exchange with the body fluids and these are brittle and weak in nature (Larsson and Hannink, 2011). The main advantages of calcium sulphate are biocompatibility, complete resorption in a relatively short period, conferred osteoconductive properties as well as relatively low cost and easy application (Szponder et al., 2013). Thus by combining fast resorbing calcium sulphate and slow resorbing calcium phosphate cements ,composite materials have been developed that might enhance vascular infiltration and replacement of the graft by new bone while providing osteoconductive and mechanical support (Johnson et al., 1996). Calcium sulphate is a material with high surgical flexibility and its physical
properties like hygroscopicity and plasticity allows its easy application in the filling of the bony defect in small animals without the risk of biomaterial displacement to surrounding soft tissue (Szponder et al., 2013).

**Bioactive Glass**

Bioactive glass ceramics also known as bioglass composed of silica, sodium oxide, calcium oxide and phosphates are biocompatible and osteoconductive in nature and binds to bone without an intervening fibrous connective tissue interface (Zhang et al., 2009). This material is used either alone or in combination with other bone grafts or substitutes in the form of composites for bone defects. It acts as a scaffold on which newly formed bone can be deposited after vascular in growth and osteoblast differentiation (Nandi et al., 2010). Bioglass was found to trigger new bone formation by allogenic demineralized bone matrix and the biocompatibility of the glass was verified by the absence of adverse cellular reactions (Pajamaki et al., 1993).

**Biodegradable/Bioabsorbable Polymers**

Biodegradable organic based porous scaffolds like poly(lactide), polyglycolide or co-polymers formed from these materials (Laurencin and Lane, 1994) are used as bone graft substitutes. Traditionally such materials have been used to design various screws, plates, pins and rods. Modern practice involves the use of such synthetic polymers for the purpose of fabricating tissue engineered scaffolds with potential to promote in vivo bone ingrowth and subsequently repair or regenerate bone to replace missing tissue (Asti and Gioglio, 2014). These materials provide a scaffold over which the osteoblasts are able to lay down the matrix and enhance healing by creeping osteogenesis. Their relatively low modulus and strength properties make them unsuitable for load bearing bone substitute applications (Pilliar et al., 2001). Biopolymers have also been used as carriers of growth factors mainly bone morphogenetic proteins. Although synthetic polymers can offer wide advantage including controlled degradation, biocompatibility, mechanical stability and many more, they lacks osteoconductivity (Salmasi et al., 2016).

**Polymethylmethacrylate (PMMA)**

Polymethylmethacrylate commercially known as Bone Cement was introduced by Charnley and Smith in the late 1960s. PMMA have been considered as the gold standard in joint arthroplasty (Huang et al., 2012). PMMA can be moulded into different shapes and sizes (Vardhan et al., 2017), confirms to the shape of the surroundings, allows even distribution of implant loads and forms a strong mechanical bond with the implants (Kim et al., 2004). PMMA are available as two component systems. It consist of a powder and a liquid monomer which when mixed result in a polymerization reaction forming polymethylmethacrylate. PMMA has been used since long time for hip arthroplasty procedures in human medicine and stabilisation of vertebral fractures and luxations in veterinary. PMMA acts as a space filler that creates a tight space which holds the implant against the bone (Vaishya et al., 2013) and therefore finds significant use in fracture sites where implant loosening is a problem. The use of PMMA has several potential disadvantages including complications associated with exothermic polymerization and potential to serve as nidus of infection should the PMMA be contaminated (Lanz et al., 1999).

**Summary**

Non-union is a common complication following long bone fracture with defects and its incidence depends on the location and severity of the injury to the bone, soft tissue and vascular structure (Sen and Miclau, 2007). Various biological bone grafts have been used for osteogenesis, osteoconduction and even osteoinduction, but due to systemic influences and local factors the outcome of successful incorporation of a bone graft has not been successful (Sharifi et al., 2002). One of the most attractive features of injectable bone substitutes, besides providing mechanical support is their potential use for controlled release of therapeutic or bioactive agents (Sun et al., 2007). Calcium phosphate and hydroxyapatite ceramics are considered among the most promising bone substitutes because of their bone like chemical composition and mechanical properties (Mastrogiacomo et al., 2006). In the future, control of bone regeneration with strategies that mimic the normal cascade of bone formation will offer successful management of conditions requiring enhancement of bone regeneration and reduce their morbidity and cost in the long term (Dimitriou et al., 2011). As an alternative to local augmentation of the bone regeneration process, the use of systemic agents including growth hormone and parathyroid hormone is also under extensive research (Dimitriou et al., 2011).
References:

1. Anderson, K.J. (1961). The behaviour of autogenous and homogenous bone transplants in the anterior chamber of the rats eye: A histological study of the effect of the size of the implant. J. Bone Joint Surg. Am. 43(A): 454-464.

2. Asti, A. and Gioglio, L. (2014). Natural and synthetic biodegradable polymers: different scaffolds for cell expansion and tissue formation. Int. J. Artif. Organs. 37(3): 187-205.

3. Babis, G.C. and Soucacos, P.N. (2005). Bone scaffolds: The role of mechanical stability and instrumentation. Injury. 36(Suppl): S38-S44.

4. Basset, C.A.L. (1972). Clinical implications of cell function in bone grafting. Clin. Orthop. Rel. Res. 87: 49-59.

5. Bauer, T.W. and Muschler, G.W. (2000). Bone Graft Materials: An overview of Basic science. Clin. Orthop. Relat. Res. 371: 10-27.

6. Beaumont, P. (1970). Fracture of acrylic bone cement. Lancet. 860.

7. Bishnoi, A.K. (2013). Studies on Efficacy ofComposite Bone Grafts in Comminuted Long Bone Fracture Healing Stabilised by Intramedullary Interlocking Nailing in Canines. Part of Ph. D thesis submitted to Guru Angad Dev Veterinary and Animal Sciences University.

8. Bohatyrewicz, A., Bohatyrewicz, R., Klek, R., Kaminski, A., Dobiecki, K., Bialecki, P., et al. (2006). Factors determining the contamination of bone tissue procured from cadaveric and multiorgan donors. Transplant Proc. 38: 301-304.

9. Bostman, O.A. (1991). Current concepts review absorbable implants for the fixation of fractures. J. Bone Joint Surg. 73(A): 148-153.

10. Bostrom, M. P., Saleh, K. J., Einhorn, T. A. (1999). Osteoinductive growth factors in preclinical fracture and long bone defects models. Orthop. Clin. North Am. 30: 647-58.

11. Cheng, L., Ye, F., Yang, R., Lu, X., Shi, Y., Li, L., Fan, H. and Bu, H. (2010). Osteoinduction of hydroxyapatite/beta-tricalcium phosphate bioceramics in mice with a fractured fibula. Acta Biomaterialia. 6: 1569-1574.

12. Cho, T.J., Gerstenfeld, L.C. and Einhorn, T.A. (2002). Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J. Bone Miner. Res. 17: 513-520.

13. Chow, L.C. (2009). Next generation calcium phosphate- based biomaterials. Dent. Mater. J. 28(1): 1-10.

14. Connolly, J. F. (1995). Injectable bone marrow preparations to stimulate osteogenic repair. Clin. Orthop. Relat. Res. 313: 8-18.

15. Dimitriou, R., Jones, E., McGonagle, D. and Giannoudis, P.V. (2011). Bone regeneration: Current concepts and future directions. BMC Medicine. 9: 66.

16. Einhorn, T.A. (1998). The cells and molecular biology of fracture healing. Clinical Orthopaedic Related Research. 355: 7-21.

17. Fidancevská, E., Rúseška, G., Bossert, J., Lin, Y. M. and Boccaccini, A.R. (2007). Fabrication and characterization of porous bioceramic composites based on hydroxyapatite and titania. Mater. Chem. Phys. 103: 95–100.

18. Gazdag, A.R., Lane, J.M., Glaser, D. and Forster, R.A. (1995). Alternatives to autogenous bone graft: efficacy and indications. J. Am. Acad. Orthop. Surg. 3: 1-8.

19. Ghosh, S.K., Nandi, S.K., Kundu, B., Datta, S., De, D.K., Roy, S.K., et al. In vivo response of porous hydroxyapatite and beta Tricalcium phosphate prepared by aqueous solution combustion method and comparison with bioglass scaffolds. J. Biomed Mater Res B Appl Biomater. 86: 217-227.

20. Giannoudis, P.V. and Einhorn, T.A. (2009). Bone Morphogenetic Proteins in Musculoskeletal Medicine. Injury. 40(Suppl 3): S1-3.

21. Groeneveld, E.H., van den Bergh, J.P., Holzmann, P. et al. (1999). Mineralization processes in demineralized bone matrix grafts in human maxillary sinus floor elevations. J. Biomed. Mater. Res. 48(4): 393-402.

22. Habibovic, P. and de Groot, K. Osteoinductive biomaterials-properties and relevance in bone repair. J. Tissue Eng. Regen. Med. 1: 25-32.
26. Hannouche, D., Petite, H. and Sedel, L. (2001). Current Trends in the Enhancement of Fracture Healing. The Journal of Bone and Joint Surgery. 83(B): 157-164.
27. Huang, S., Wen, Bo., Bian, W. and Yan, H. (2012). Reconstruction of Comminuted long bone fracture using CF/CPC scaffolds manufactured by rapid prototyping. Med. Sci. Monit. 18(11): 435-440.
28. Johnson, K.A. (1986). Cancellous bone graft collection from the tibia in dogs. Veterinary Surgery. 15: 334-338.
29. Johnson, K.D., Frierson, K.E., Keller, T.S., Cook, C., Scheinberg, R., Zerwekh, J., Meyers, L. and Scandini, M.F. (1996). Porous ceramics as bone graft materials in long bone defects: a biomechanical, histological and radiographic analysis. J. Orthop. Res. 14:351-369.
30. Khan, S.N., Cammisa, F.P., Sandhu, H.S., Diwan, A.D., Girardi, F.P. and Lane, J.M. (2005). The biology of bone grafting. J. Am. Acad. Orthop. Surg. 13: 77-86.
31. Kontakis, G.M., Pagkalos, J.E., Tosounidis, T.I., Melissas, J. and Katonis, P. (2007). Bioabsorbable materials in orthopaedics. Acta Orthop. Belg. 73: 159-169.
32. Kim, S.K., Kim, Y.J., Yoon, T.L., Park, Su. A., Cho, I.H., Kim, E.J., Kim, I.A. and Shin, J.W. (2004). The characteristics of hydroxyapatite-chitosan-PHEMA bone cement. Biomaterials. 25: 5715-5723.
33. Lanz, O.I., Lewis, D.D., Madison, J.B., Miller, G.J. and Martin, D.E. (1999). A Biomechanical comparison of screw and wire fixation with and without polymethylmethacrylate reinforcement for acetabular osteotomy stabilisation in dogs. Veterinary Surgery. 28: 161-170.
34. Larsson, S. (2006). Cement Augmentation in fracture treatment. Scandinavian Journal of Surgery. 95: 111-118.
35. Larsson, S. and Hannink, G. (2011). Injectable bone graft substitutes: Current products, their characteristics and indications and new developments. Injury. 42: S30-S34.
36. Laurencin, C.T. and Lane, J.M. (1994). Poly (lactic acid) and poly(glycolic acid): orthopaedic surgery applications. In: Brighton, C.T., Friedlaender, G. and Lane, J.M. editors. Bone formation and repair. Rosemcut, IL: American Academy of Orthopaedic Surgeons. p. 325-339.
37. Laursen, M., Christensen, F.B., Burger, C. and Lind, M. (2003). Optimal handling of fresh cancellous bone graft: Different preoperative storing techniques evaluated by in vitro osteoblast like cello metabolism. Acta Orthop. Scand. 74: 490-496.
38. Marx, R.E. and Wong, M.E. (1987). A technique for the comparession and carriage of autogenous bone during bone grafting procedures. J. Oral Maxillofac. Surg. 45: 988-989.
39. Mukherjee, D.P., Tunkle, A.S., Roberts, R.A., Clavenna, A., Rogers, S. and Smith, D. (2003). An Animal evaluation of a paste of chitosan glutamate and hydroxyapatite as a synthetic bone graft material. J. Biomed. Mater. Res. B Appl. Biomater. 67B: 603-609.
40. Nandi, S.K., Roy, S., Mukherjee, P., Kundu, B., De, D.K. and Basu, D. (2010). Orthopaedic Application of bone graft and graft substitutes: a review. Indian J. Med. Res. 132:15-30.
41. Noshi, T., Yoshikawa, T., Ikeuchi, M., Dohi, Y., Ohgushi, H., Horiuchi, K., et al. (2000). Enhancement of the invitro osteogenic potential of narrow/ hydroxyapatite composites by bovine bone morphogenetic protein. J. Biomed. Mater. Res. 52: 621-630.
42. Outhayoun, J.P., Shabana, A.H.M., Issahakian, S., Patat, J.L., Guillemin, G., Sawaf, M.H. and Forest, N. (1992). Histological evaluation of natural coral skeleton as grafting material in miniature swine mandible. J. Mater. Sci. Mater. Med. 3: 222-228.
43. Pajamaki, K.J., Andersson, O.H., Lindholm, T.S., Karlsson, K.H. and Yli-Urpo, A. (1993). Induction of new bone by allogenic demineralized bone matrix combined to bioactive glass composite in the rat. Ann. Chirug. Gynaecol. 207(Suppl): 137-143.
44. Penwick, R. C., Mosier, D. A. and Clark, D. M. (1991). Healing of canine autogenous bone graft donor sites. Veterinary Surgery 20: 229-234.
45. Perry, C.R. (2000). Bone repair techniques, bone graft and bone graft substitutes. Clin Orthop Relat Res. 360: 71-86.
46. Pilliar, R.M., Filiaggi, M.J., Wells, J.D., Grynpas, M.D. and Kandel, R.A. (2001). Porous calcium polyphosphate scaffolds for bone graft applications- in vitro characterization. Biomaterials. 22: 963-972.
47. Popkov, A.V., Popkov, D.A., Kononovich, N.A., Gorbuch, Ye. N., Ir’ianov, Yu. M., Tverdoklebov, S.I. and Bol’basov, Ye. N. (2016). Osseointegration of the intramedullary implant in fracture of the diaphysis of a long bone. Journal of Global Pharma Technology. 11(8): 01-07.
48. Refai, A.K., Textor, M., Brunette, D.M. and Waterfield, J.D. (2004) Effect of titanium surface topography on macrophage activation and secretion of proinflammatory cytokines and chemokines. J. Biomed. Mater. Res. A. 70:194-205.
49. Salmasi, S., Nayyer, L., Seifalian, A.M. and Blunn, G.W. (2016). Nanohydroxyapatite Effect on the Degradation, Osteoconduction and Mechanical Properties of Polymeric Bone Tissue Engineered Scaffolds. The Open Orthopaedic Journal. 10(Suppl-3): 900-919.

50. Samartzis, D., Shen, F.H., Goldberg, E.J. and An, H.S. (2005). Is autograft the gold standard in achieving radiographic fusion in one level anterior cervical discectomy and fusion with rigid anterior plate fixation? Spine. 30: 1756-1761.

51. Sen, M. K. and Miclau, T. (2007). Autologous iliac crest bone graft: should it still be the gold standard for treating non-unions? Injury. 38(1): 75-80.

52. Sun, L., Xu, H.H., Takagi, S. and Chow, L.C. (2007). Fast setting calcium phosphate cement –chitosan composite: mechanical properties and dissolution rates. J. Biomater Appl. 21(3): 299-315.

53. Szponder, T., Mytnik, E. and Jaegermann, Z. (2013). Use of calcium sulphate as a biomaterial in the treatment of bone fractures in rabbits- preliminary study. Bull. Vet. Inst. Pulawy. 57: 119-122.

54. Tay, B. K., Patel, V. V. and Bradford, D. S. (1999). Calcium sulfate- and calcium phosphate based bone substitutes. Mimicry of the mineral phase of bone. Orthop. Clin. North Am. 30 (4): 615-23.

55. Vaccaro, A.R. (2002). The role of osteoconductive scaffold in synthetic bone graft. Orthopaedics. 25: S571-S578.

56. Vaishya, R., Chauhan, M. and Vaish. A. (2013). Bone Cement. Journal of Clinical Orthopaedics and Trauma. 4: 157-163.

57. Vardhan, K.H., Prasad, V.D., Sreenu, M. and Syaamsundar, N. (2017). Histopathological Evaluation of Poly methyl Methacrylate and Hydroxyapatite Implants for Fracture Healing in Rabbits. R.R.Jo.V.S.T. 6(3): 3-6.

58. Venkatesan, J. and Kim, S.K. (2014). Nano-hydroxyapatite composite biomaterials for bone tissue engineering review. J. Biomed Nanotechnol. 8(9): 5744-5794.

59. Welch, R.D., Zhang, H. and Bronson, D.G. (2003). Experimental tibial plateau fractures augmented with calcium phosphate cement or autologous bone graft. J. Bone Joint Surg. Am. 67: 105-112.

60. Younger, E.M. and Chapman, M. W. (1989). Morbidity at bone graft donor sites. J. Orthop. Trauma. 3(3):192-195.

61. Yuan, H., Chen, N, Lu, X. and Zhen, B. Experimental study of natural hydroxyapatite/chitosan composite on reconstructing bone defects. J. Nanjing Med. Univ. 22: 6372-6375.

62. Zamprogno, H. C. D. D. M. (2004). Evaluation of bone grafting materials in cats: A comparison of cancellous autograft, cancellous allograft and bioglass in a femoral defect model. M.Sc., Mississippi State University.

63. Zhang, H., Ye, X.J. and Li, J.S. (2009). Preparation and biocompatibility evaluation of apatite/wollastonite-derived porous bioactive glass ceramic scaffolds. Biomed Mater. 4:450-457.